论文部分内容阅读
[目的]探讨参芪扶正注射液联合重组人白介素-2(IL-2)对气血双亏型胃癌患者的治疗效果。[方法 ]将50例气血双亏型胃癌患者分成对照组(重组人白介素-2治疗组25例)和试验组(参芪扶正注射液联合重组人白介素-2治疗组25例),分别观察2组患者治疗前后生存质量、免疫功能指标及肿瘤标志物水平变化,并进行对比。[结果]试验组治疗前后免疫功能指标及肿瘤标志物水平差异均有统计学意义(P<0.05),与对照组比较差异更为显著,且在改善生存质量方面试验组明显优于对照组。[结论]参芪扶正注射液联合重组人白介素-2治疗气血双亏型胃癌效果较好。
[Objective] To investigate the therapeutic effect of Shenqi Fuzheng injection combined with recombinant human interleukin-2 (IL-2) on patients with double-deficient gastric cancer. [Methods] Fifty cases of double-deficient gastric cancer patients were divided into control group (25 cases in recombinant human interleukin-2 treated group) and experimental group (25 cases in treated group treated with Shenqi Fuzheng injection combined with recombinant human interleukin-2) The quality of life, immune function index and tumor marker level in two groups before and after treatment were compared and compared. [Results] The immune function indexes and tumor marker levels in experimental group before and after treatment were significantly different (P <0.05), compared with the control group, the difference was more significant, and the experimental group was significantly better than the control group in improving quality of life. [Conclusion] Shenqi Fuzheng injection combined with recombinant human interleukin-2 in treatment of qi and blood double-deficient gastric cancer is better.